HOUSTON, Feb. 11, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the
"Company"), a biotechnology company specializing in the
development of novel treatments for brain tumors, today announced
its plan to initiate a Phase I clinical trial for Berubicin in
pediatric brain cancer in Poland
in collaboration with WPD Pharmaceuticals, Inc. (CSE: WBIO)
("WPD"), a Polish corporation founded by Dr. Waldemar Priebe, the founder of the Company.
The Company, in collaboration with WPD, will conduct the
upcoming Phase I clinical trial at Children's Memorial Health
Institute ("Children's Memorial"), the largest pediatric
hospital in Poland. The Company
believes this Phase I trial of Berubicin at Children's Memorial
represents the first ever investigation of an anthracycline and
topoisomerase II inhibitor in pediatric brain tumors. WPD and CNS
are currently working with Children's Memorial to complete
documentation for the upcoming study and EMA scientific advice
meeting.
As previously announced, CNS entered into a sublicense agreement
with WPD which granted WPD commercial rights in a limited territory
to Berubicin, including research and development. Subsequently, WPD
was awarded a $6 million grant from
the EU/Polish National Center for Research and Development. WPD
plans to utilize funds from the grant to fund the upcoming Phase I
trial and CNS is committed to fully support these studies with its
internal expertise.
"We are extremely excited to further expand the scope
of Berubicin and potentially bring a new hope for pediatric brain
tumor patients in Poland and
subsequently around the world," stated John
Climaco, CEO of CNS Pharmaceuticals. "We look forward to
initiating what we believe to be the first investigation of a
unique topoisomerase II inhibitor that appears to be able to cross
the blood-brain barrier in pediatric brain tumors as we
continue to drive the clinical development of Berubicin in the
upcoming Phase II trial in adult patients."
About Berubicin
Berubicin is an anthracycline, a class
of anticancer agents that are among the most powerful chemotherapy
drugs and effective against more types of cancer than any other
class of chemotherapeutic agents. Anthracyclines are designed to
utilize natural processes to induce deoxyribonucleic acid (DNA)
damage in targeted cancer cells by interfering with the action of
topoisomerase II, a critical enzyme enabling cell proliferation.
Berubicin treatment of brain cancer patients appeared to
demonstrate positive responses that include one durable complete
response in a Phase 1 human clinical trial conducted by Reata.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is
a biotechnology company specializing in the development of novel
treatments for primary and metastatic brain and central nervous
system tumors. Its lead candidate Berubicin is proposed for the
treatment of glioblastoma, a type of brain cancer currently
considered incurable, as well as for pancreatic and ovarian
cancers, and lymphomas. The Company entered into an intellectual
property (IP) agreement with Houston Pharmaceuticals, Inc. and a
Purchase Agreement with Reata. For more information, visit
www.cnspharma.com.
Forward-Looking Statements
Some of the statements in
this release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of the Company to further
the clinical development of Berubicin in the United States and Poland. These statements relate to future
events, future expectations, plans and prospects. Although CNS
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. CNS has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
in our SEC filings, including under the heading "Risk Factors" in
the Form S-1 we filed with the SEC on October 7, 2019. Any forward-looking statements
contained in this release speak only as of its date. CNS undertakes
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-collaboration-with-european-partner-to-expand-clinical-trials-to-pediatric-brain-tumors-301002040.html
SOURCE CNS Pharmaceuticals, Inc.